CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D)....
Specific stem cells are thought to be the origin of many, if not
all, cancers and although there are several drugs in clinical
trials, only small companies are currently conducting research in
Cellartis has begun a new research programme in Scotland as part of
a £9.5m (€14.5m) programme by ITI Life Sciences to develop the
world's first automated process to produce high-quality human stem
Researchers at the University of Rochester and StemCapture have
unveiled a new device technology that makes it possible to harvest
stem cells from the blood, bypassing the controversial use of stem
cells sourced from embryos.
According to a new report, worldwide revenues for cell and cytokine
therapies in regenerative medicine are set to reach $20.7 billion
(€17.3 billion) in 2010 in a sector that provides a viable
alternative to using drugs or other therapies.
Stem cells have the potential to become an effective diagnostic
tool singling out those susceptible of atherosclerosis, say
researchers. These cells could also help to predict regeneration of
heart cells following a heart attack.
Scientists in the UK are tipped to be given approval this week to
create cloned human embryos to harvest stem cells to treat diabetes
patients and with the possibility of treating other diseases such
as Parkinson's and Alzheimer's.
Scientists in South Korea have isolated stem cells from a cloned
human embryo for the first time, bringing the use of cell- or
tissuse-based therapies for treating disease a step nearer. But the
work has also re-ignited the controversy...